These are the stocks posting the largest moves in premarket trading.
Check out the companies making headlines before the bell. Eli Lilly — Eli Lilly shares rose 2% after a panel of FDA advisors recommended the approval of its Alzheimer's drug known as donanemab. General Motors — The automaker's stock added more than 1% after its board authorized a $6 billion stock buyback program . Shopify — The e-commerce stock rose about 1% after JPMorgan initiated coverage with an overweight rating.
DXC Technology — Shares of DXC Technology rose 3% following a Reuters report that Apollo Global and Kyndryl Holdings are making a joint bid for the information technology company, reportedly offering between $22 and $25 a share. GameStop — GameStop shares slipped 1% before the bell, continuing its volatile ride.
Kyndryl Holdings Inc Calavo Growers Inc Gamestop Corp DXC Technology Co Apple Inc Shopify Inc Shopify Inc General Motors Co Eli Lilly And Co Business Breaking News: Markets Stock Markets Economy Markets Market Insider Breaking News Business News
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Apple, Coinbase, Yext fall premarket; GM, Eli Lilly riseApple, Coinbase, Yext fall premarket; GM, Eli Lilly rise
Read more »
Alzheimer’s drug from Eli Lilly wins backing of FDA committeeAn advisory committee to the Food and Drug Administration found the drug was safe and effective at slowing the progression of the disease, setting the stage for the agency to approve it.
Read more »
FDA advisors recommend Eli Lilly Alzheimer’s drug that slows diseaseEli Lilly's new Alzheimer's drug, donanemab, received approval from an advisory panel for the FDA. The full agency is expected to approve the drug by spring.
Read more »
FDA advisors recommend Eli Lilly's Alzheimer's drug donanemab, paving way for approvalIf approved, Eli Lilly’s donanemab would become the second Alzheimer’s drug of its kind to enter the market after Leqembi from Biogen and Eisai.
Read more »
FDA advisors recommend Eli Lilly's Alzheimer's drug donanemab, paving way for approvalIf approved, Eli Lilly's donanemab would become the second Alzheimer's drug of its kind to enter the market after Leqembi from Biogen and Eisai.
Read more »
FDA analysis raises no major concerns about Eli Lilly Alzheimer's drugAn FDA analysis of trial data for Eli Lilly's experimental Alzheimer's drug donanemab released on Thursday revealed no red flags, but raised questions about safety of the treatment for patients with early-stage disease.
Read more »